Display options
Cite
Hoimark L, Laursen T, Rungby J. Potential role of linagliptin as an oral once-daily treatment for patients with type 2 diabetes. Diabetes Metab Syndr Obes. 2012;5:295-302doi: 10.2147/DMSO.S16288.
Hoimark, L., Laursen, T., & Rungby, J. (2012). Potential role of linagliptin as an oral once-daily treatment for patients with type 2 diabetes. Diabetes, metabolic syndrome and obesity : targets and therapy, 5295-302. https://doi.org/10.2147/DMSO.S16288
Hoimark, Lene, et al. "Potential role of linagliptin as an oral once-daily treatment for patients with type 2 diabetes." Diabetes, metabolic syndrome and obesity : targets and therapy vol. 5 (2012): 295-302. doi: https://doi.org/10.2147/DMSO.S16288
Hoimark L, Laursen T, Rungby J. Potential role of linagliptin as an oral once-daily treatment for patients with type 2 diabetes. Diabetes Metab Syndr Obes. 2012;5:295-302. doi: 10.2147/DMSO.S16288. Epub 2012 Aug 23. PMID: 22952411; PMCID: PMC3430084.
Copy Download .nbib Format: NLM
Share it on

Diabetes Metab Syndr Obes. 2012;5:295-302. doi: 10.2147/DMSO.S16288. Epub 2012 Aug 23.

Potential role of linagliptin as an oral once-daily treatment for patients with type 2 diabetes.

Diabetes, metabolic syndrome and obesity : targets and therapy

Lene Hoimark, Torben Laursen, Jørgen Rungby

Affiliations

  1. Department of Biomedicine - Pharmacology and Clinical Pharmacology, Aarhus University Hospital and Aarhus University, Aarhus, Denmark.

PMID: 22952411 PMCID: PMC3430084 DOI: 10.2147/DMSO.S16288

Abstract

BACKGROUND: Linagliptin is an oral antihyperglycemic agent that selectively inhibits the enzyme dipeptidyl peptidase-4 (DPP-4). Inhibition of DPP-4 increases the levels of the incretin hormones glucagon-like peptide and glucose-dependent insulinotropic polypeptide by preventing their degradation.

OBJECTIVE: We reviewed the role of linagliptin as an oral once-daily treatment for patients with type 2 diabetes.

METHODS: A comprehensive literature search was performed using the term "linagliptin." Original research articles and review articles were included in our examination.

RESULTS: Linagliptin has a similar mode of action as other gliptins, with comparable efficacy, safety profile, and tolerability. Differences in pharmacokinetic parameters that distinguish linagliptin from other gliptins include that linagliptin is not renally excreted and does not require dose reduction with renal impairment.

CONCLUSION: Linagliptin is an oral, once-daily, antihyperglycemic agent that significantly reduces glycated hemoglobin (HbA(1c)) when used alone or in combination with other antidiabetic drugs in people with type 2 diabetes. Pharmacokinetics, such as the lack of renal excretion, distinguishes linagliptin from other gliptins.

Keywords: DPP-4 inhibitors; linagliptin; type 2 diabetes

References

  1. J Clin Pharmacol. 2008 Oct;48(10):1171-8 - PubMed
  2. Expert Opin Pharmacother. 2011 Dec;12(17):2759-62 - PubMed
  3. Diabetes Obes Metab. 2012 May;14(5):470-8 - PubMed
  4. Drug Metab Pharmacokinet. 2011;26(2):123-9 - PubMed
  5. Curr Med Res Opin. 2009 Aug;25(8):1963-72 - PubMed
  6. Clin Pharmacokinet. 2010 Dec;49(12):829-40 - PubMed
  7. Diabetes Obes Metab. 2011 Mar;13(3):258-67 - PubMed
  8. Diabetes Obes Metab. 2011 Jan;13(1):65-74 - PubMed
  9. Diabetes Obes Metab. 2009 Aug;11(8):786-94 - PubMed
  10. Clin Ther. 2011 Aug;33(8):1096-103 - PubMed
  11. Curr Med Res Opin. 2011 Nov;27 Suppl 3:57-64 - PubMed
  12. Expert Opin Investig Drugs. 2010 Jan;19(1):133-40 - PubMed
  13. Int J Clin Pharmacol Ther. 2010 Oct;48(10):652-61 - PubMed
  14. Diabetes Obes Metab. 2011 Jul;13(7):653-61 - PubMed
  15. Drugs. 2011 Jul 30;71(11):1441-67 - PubMed
  16. Diabet Med. 2011 Nov;28(11):1352-61 - PubMed
  17. J Med Chem. 2007 Dec 27;50(26):6450-3 - PubMed
  18. Drug Metab Dispos. 2010 Apr;38(4):667-78 - PubMed
  19. Br J Clin Pharmacol. 2012 Jul;74(1):75-85 - PubMed
  20. Diabetes Obes Metab. 2011 Oct;13(10):939-46 - PubMed
  21. Clin Ther. 2011 Jul;33(7):973-89 - PubMed
  22. Adv Ther. 2012 Jan;29(1):14-25 - PubMed
  23. Expert Opin Pharmacother. 2012 Jan;13(1):81-99 - PubMed
  24. Cardiovasc Diabetol. 2012 Jan 10;11:3 - PubMed
  25. Expert Opin Pharmacother. 2012 Jan;13(1):101-10 - PubMed
  26. Diabetes Obes Metab. 2011 Jun;13(6):542-50 - PubMed
  27. Adv Ther. 2011 Jun;28(6):447-59 - PubMed
  28. J Cardiovasc Pharmacol. 2011 Aug;58(2):157-66 - PubMed
  29. Exp Diabetes Res. 2011;2011:810469 - PubMed

Publication Types